You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新鋭醫藥(06108.HK)中期扭虧為盈至113.3萬港元
格隆匯 08-31 20:47

格隆匯8月31日丨新鋭醫藥(06108.HK)公吿,截至2021年6月30日止6個月,集團錄得收益約2.14億港元,同比增加約208.8%。集團於截至2020年6月30日止6個月公司擁有人應占虧損淨額約3643.4萬港元,而於截至2021年6月30日止6個月則轉為錄得公司擁有人應占溢利淨額約113.3萬港元,扭虧為盈;董事會不建議派付截至2021年6月30日止6個月的任何中期股息(2020年:零)。

期內,集團收益於中國由以下各項收益貢獻:(i)醫藥產品分銷及貿易;及(ii)提供營銷及推廣服務。集團分銷主要醫藥產品類別為注射劑藥品。

收益增加主要由於集團主要產品二代頭孢產品("該產品")(1.0g)銷量增加。在2021年上半年,鑑於Covid-19在中國的傳播已受控制,中國的宏觀經濟正在恢復。

另一方面,中國各城市放寬人口流動限制,導致尋求醫療服務及醫院服務的人數有所增加。因此,於期內,對醫藥產品的需求一直增加。同時,通過在期內積極組織及參與中國各種學術推廣活動,集團該產品(1.0g)的銷售額自2019年九月恢復生產及銷售該產品(1.0g)以來一直逐步增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account